250,000 shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) acquired by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC bought a new position in Puma Biotechnology, Inc. (NASDAQ:PBYI – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 250,000 shares of the biopharmaceutical company’s stock, valued at approximately $815,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of PBYI. Squarepoint Ops LLC grew its stake in Puma Biotechnology by 17.7% in the second quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 10,757 shares during the last quarter. Great Point Partners LLC boosted its holdings in shares of Puma Biotechnology by 10.6% in the second quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock worth $4,846,000 after purchasing an additional 142,916 shares during the period. Renaissance Technologies LLC increased its position in shares of Puma Biotechnology by 1.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,753,013 shares of the biopharmaceutical company’s stock worth $5,715,000 after buying an additional 23,600 shares. shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Puma Biotechnology by 6.6% in the second quarter. Dimensional Fund Advisors LP now owns 605,977 shares of the biopharmaceutical company’s stock valued at $1,975,000 after buying an additional 37,684 shares during the period. Finally, WINTON GROUP Ltd boosted its stake in Puma Biotechnology by 59.7% in the second quarter. WINTON GROUP Ltd now owns 300,599 shares of the biopharmaceutical company’s stock worth $980,000 after acquiring an additional 112,316 shares during the period. Hedge funds and other institutional investors own 61.29% of the company’s shares.

Changes in Analyst Ratings

A number of research analysts have commented on the stock. StockNews.com downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a report on Friday, August 2nd.

Get our latest analysis on PBYI

Indoor activity

In related news, Director Michael Patrick Miller sold 23,358 shares of Puma Biotechnology stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $3.49, for a total value of $81,519.42. Following the completion of the sale, the director now directly owns 47,000 shares in the company, valued at approximately $164,030. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC’s website. In other news, CEO Alan H. Auerbach sold 21,920 shares of Puma Biotechnology stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $3.70, for a total transaction of $81,104.00. Following the completion of the transaction, the chief executive officer now directly owns 7,063,515 shares of the company’s stock, valued at approximately $26,135,005.50. The transaction was disclosed in a legal filing with the SEC, which is available on the SEC’s website. Also, Director Michael Patrick Miller sold 23,358 shares of the stock in a transaction on Monday, August 12th. The shares were sold at an average price of $3.49, for a total transaction of $81,519.42. Following the sale, the director now directly owns 47,000 shares in the company, valued at $164,030. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold a total of 82,263 shares of company stock worth $286,469. 23.70% of shares are currently owned by corporate insiders.

Puma Biotechnology stock performance

PBYI opened at $2.55 on Wednesday. The company has a current ratio of 1.32, a quick ratio of 1.23, and a debt-to-equity ratio of 0.90. The firm has a market cap of $125.08 million, a price-to-earnings ratio of 7.73 and a beta of 1.09. Puma Biotechnology, Inc. has a 12-month low of $2.13 and a 12-month high of $7.73. The stock has a fifty day moving average price of $3.00 and a 200 day moving average price of $3.88.

Puma Biotechnology (NASDAQ:PBYI – Get Your Free Report ) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. Puma Biotechnology had a return on equity of 18.36% and a net margin of 4.01%. The firm had revenue of $47.10 million during the quarter, compared to analysts’ expectations of $43.99 million. In the same quarter last year, the firm earned $0.05 EPS. As a group, equities research analysts anticipate that Puma Biotechnology, Inc. will post 0.25 earnings per share for the current fiscal year.

Puma Biotechnology Profile

(Free Report)

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on developing and commercializing products to improve cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib, which is used to treat adult patients with early-stage HER2-overexpressing/amplified breast cancer; and HER2-positive advanced or metastatic breast cancer when combined with capecitabine.

Featured stories

Want to see what other hedge funds PBYI owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Puma Biotechnology, Inc. (NASDAQ:PBYI – Free Report).

Get news and reviews for Puma Biotechnology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Puma Biotechnology and related companies with MarketBeat.com’s FREE daily email newsletter.